TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Inventories
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Inventories of -$2.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$198.00K, a 116.95% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $196.00K, a 133.33% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $536.00K.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$37.00K, a 105.67% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2025 was $1.75M, a 14.42% decline from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2024 was $2.05M, a 34.15% decline from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2023 was $3.11M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$198.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.00K 10-Q · filed 2026-08-06 | $534.00K derived: sum of 3 quarters · filed 2026-08-06 | $497.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $196.00K 10-Q · filed 2026-05-06 | $732.00K derived: sum of 2 quarters · filed 2026-05-06 | $695.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $536.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $499.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.67M derived: sum of 3 quarters · filed 2026-08-06 | $1.75M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.13M derived: sum of 2 quarters · filed 2026-08-06 | $1.22M 10-Q · filed 2025-11-04 | $988.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.25M 10-Q · filed 2026-08-06 | $1.02M derived: sum of 3 quarters · filed 2026-08-06 | $1.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $84.00K 10-Q · filed 2026-05-06 | -$143.00K derived: sum of 2 quarters · filed 2026-05-06 | $509.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.20M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $425.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.12M derived: sum of 3 quarters · filed 2026-02-23 | $2.05M 10-K · filed 2026-02-23 |
| 2024-09-30 | $652.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.34M derived: sum of 2 quarters · filed 2025-11-04 | $2.27M 10-Q · filed 2025-11-04 | $5.37M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $692.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.62M 10-Q · filed 2025-08-06 | $4.71M derived: sum of 3 quarters · filed 2026-02-23 | $4.73M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $929.00K 10-Q · filed 2025-05-01 | $4.02M derived: sum of 2 quarters · filed 2026-02-23 | $4.04M derived: sum of 3 quarters · filed 2026-02-23 | $4.04M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.11M derived: sum of 2 quarters · filed 2026-02-23 | $3.11M derived: sum of 3 quarters · filed 2026-02-23 | $3.11M 10-K · filed 2026-02-23 |
| 2023-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $15.00K derived: sum of 2 quarters · filed 2024-11-13 | $15.00K 10-Q · filed 2024-11-13 | $15.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |